Dr. Bajaj is a managing director at Foresite Capital, evaluating and pursuing investments at the intersection of technology and life sciences, including in personalized and precision healthcare.
Prior to joining Foresite Capital, Vik was the chief scientific officer of GRAIL and remains on its Scientific advisory board. He is also the co-founder and former chief scientific officer of Verily (formerly Google Life Sciences) and served as chair of its Scientific advisory board.
Bajaj retains appointments as associate professor at the Stanford University School of Medicine, and as an affiliate scientist of the Lawrence Berkeley National Laboratory and the University of California, Berkeley, for which he serves on the advisory board of the College of Chemistry.
He is an advisor to the Department of Defense through the Defense Science Board's Task Force on Biology.
Bajaj holds a Ph.D. in physical chemistry from the Massachusetts Institute of Technology. His scientific and engineering awards include the Anatole Abragam Prize, the R and D 100 Award for the most promising commercialized technologies (2011 and 2013), and the Department of Energy's LBL Innovation Grant.
In 2011, he was named as a Visiting Professor of the Chinese Academy of Sciences.
Quantum-Si is focused on revolutionizing the growing field of proteomics.
The company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable single molecule next-generation protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients